推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Leiomyosarcomas of Uterus

N Reed - Rare and Uncommon Gynecological Cancers, 2011 - Springer
Uterine sarcomas present a challenging group of tumours to manage, but the focus in this chapter
will be on uterine leiomyosarcomas (LMS) [1]. Nevertheless, historically these tumours have
been lumped together with carcino- sarcomas and are usually treated by Gynaecological ...
Related articles - All 2 versions

Metastatic Jaw Swelling as the Manifestation of Leiomyosarcoma of Uterus-A Case Report

[PDF] from banglajol.infoMM Hassan, M Ahmed, RA Bhuiyan… - Journal of Bangladesh …, 2011 - banglajol.info
1. Dr. Md. Mokerrom Hasan. BDS, BCS, FCPS(OMS), OSD DGHS, Deputed to Department Of
Oral and Maxillofacial Surgery, Dhaka Dental College and Hospital. 2. Prof. Mohiuddin
Ahmed. BDS, PhD(Japan), Head of the Department Of Oral and Maxillofacial Surgery, ...
Related articles - All 3 versions

[CITATION] Histopathologic Prognostic Factors in Stage I Uterine Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases

A Muzikansky… - 2011
Related articles

Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases

WL Wang, R Soslow, M Hensley… - … American Journal of …, 2011 - journals.lww.com
Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis
(15% to 25% 5-year survival rate). However, patients with stage I Ut-LMSs are reported to have
a relatively better outcome when compared with the overall group with a 5-year survival ...
Related articles - All 3 versions

[HTML] Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis …

[HTML] from nih.govS Dhingra, ME Rodriguez, Q Shen… - … Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and
metabolism. In cancer, mTOR is frequently hyperactivated and is a clinically validated target
for therapy and drug development. Biologically, mTOR acts as the catalytic subunit of two ...
Cited by 1 - Related articles - All 2 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451